A Phase 1 interventional study of L606 (Liposomal Treprostinil) Inhalation Solution 51ug and L606 Inhalation System in Pulmonary Arterial Hypertension, sponsored by Pharmosa Biopharm Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Pharmosa Biopharm Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 1, and was the 39th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2018.
This study's enrollment of 52 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
Pharmosa Biopharm Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Pharmosa Biopharm Inc. has 3 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.
L606 (Liposomal Treprostinil) Inhalation Solution and dedicated inhalation system is developed by Pharmosa Biopharm Inc. intended to improve the inconvenience, as one of the greatest impediments to patient satisfaction to current inhaled treprostinil therapy. Pharmosa's liposomal technology offers sustained release of treprostinil which enable bid treatment instead of conventional qid treatment offered by current inhaled treprostinil therapy for treatment of patients with PAH (WHO Group 1).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo group
Device: L606 Inhalation System · Other: Placebo Solution
Liposomal inhalation solution
Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug · Device: L606 Inhalation System
Single ascending dose
Also known as: Drug: L606 (Liposomal Treprostinil) Inhalation Solution
Single ascending dose
Also known as: Device: L606 Inhalation Solution
Single ascending dose
The number of treatment-emergent adverse events for L606 and placebo, including abnormal laboratory events
Frequency, severity and seriousness of adverse events (AE) including physical examination, incident of laboratory abnormalities, 12-lead ECG parameter and vital sign assessment
Time frame: From Pre-dose to Day 10
AUC0-2hr
area under curve from time zero to 2 hours postdose
Time frame: From pre-dose to 24 hours post dose
AUC0-4hr
AUC from time zero to 4 hours postdose
Time frame: From pre-dose to 24 hours post dose
AUC0-8hr
area under curve from time zero to 8 hours postdose
Time frame: From pre-dose to 24 hours post dose
AUC0-12hr
area under curve from time zero to 12 hours postdose
Time frame: From pre-dose to 24 hours post dose
AUC0-24hr
area under curve from time zero to 24 hours postdose
Time frame: From pre-dose to 24 hours post dose
AUC0-tlast
AUC from time zero to the time of the last quantifiable concentration
Time frame: From pre-dose to 24 hours post dose
AUC0-∞
area under curve from time zero to infinite
Time frame: From pre-dose to 24 hours post dose
Cmax
maximum plasma concentration
Time frame: From pre-dose to 24 hours post dose
tmax
time to Maximum Plasma Concentration
Time frame: From pre-dose to 24 hours post dose
t1/2
time to half-life
Time frame: From pre-dose to 24 hours post dose
CL/F
apparent total plasma clearance
Time frame: From pre-dose to 24 hours post dose
Vz/F
apparent volume of distribution during terminal phase
Time frame: From pre-dose to 24 hours post dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2018 to primary completion in Sep 2019, 10 months.
Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 10 months is above that.
Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →
Pharmosa Biopharm Inc.